Physician profile

Kevin E Potts

Pulmonary Disease · Warren, MI

NPI 1750366605

$1,059.08

in general payments reported to CMS, 2019-2025

20 companies · $410 in 2025

The $410 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$728.13

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $206.99 2019-2025 Tezspire, Fasenra
Boehringer Ingelheim Pharmaceuticals, INC. $153.34 2019-2023
Glaxosmithkline, LLC. $112.53 2019-2025 Trelegy Ellipta, Nucala
Acclarent, INC $103.11 2020
Insmed, INC. $88.40 2021-2025 Brinsupri, Arikayce
Genzyme Corporation $71.45 2025
Verona Pharma, INC. $49.34 2025 Ohtuvayre
Novo Nordisk INC $38.65 2025 Wegovy
Viatris Specialty LLC $33.75 2025 Yupelri
Grifols USA, LLC $29.58 2025 Prolastin-C Liquid
Regeneron Healthcare Solutions, INC. $24.88 2025 Dupixent
Ani Pharmaceuticals, INC. $24.05 2025 Purified Cortrophin Gel
Radiometer America, INC $20.33 2023
Philips North America LLC $19.31 2019
Pulmonx Corporation $16.38 2021
Show all 20 companies
CompanyGeneral paymentsYearsTop products
Mylan Specialty L.P. $15.88 2019
Electromed, INC. $13.88 2019
Circassia INC. $13.14 2019
Shire North American Group INC $12.39 2019
Sunovion Pharmaceuticals INC. $11.70 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Kevin E Potts

$1,059.08

in general payments reported 2019-2025

Years
2019-2025
Top company
Astrazeneca Pharmaceuticals LP
Context
The $410 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/261375/kevin-e-potts

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.